Monitoring treatment response in rectal cancer through circulating tumor cell dynamics: a pilot clinical study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111935" target="_blank" >RIV/00843989:_____/25:E0111935 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/25:73631678

Výsledek na webu

<a href="https://doi.org/10.1002/jso.70073" target="_blank" >https://doi.org/10.1002/jso.70073</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/jso.70073" target="_blank" >10.1002/jso.70073</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Monitoring treatment response in rectal cancer through circulating tumor cell dynamics: a pilot clinical study

Popis výsledku v původním jazyce

Background: Circulating tumor cells (CTCs) are increasingly recognized as a minimally invasive biomarker with significant potential in oncologic monitoring and prognostication. This study aimed to assess the dynamics of CTC levels in patients with rectal cancer undergoing multimodal treatment and evaluate their potential role in therapeutic decision-making. Methods: We conducted a prospective, observational study of 56 patients with histologically confirmed rectal adenocarcinoma. Patients underwent either primary surgical resection or neoadjuvant chemoradiotherapy (CRT) followed by surgery. Peripheral blood samples were collected at defined intervals and analyzed using the CytoTrack CT11TM system to detect and quantify CTCs. Results: Pretreatment CTCs were detected in 16.1% of patients. In the primary surgery group, all preoperatively positive CTC cases became negative postoperatively, although transient positivity was observed in two cases at 1 week post-surgery. In the CRT group, 35.7% of patients exhibited detectable CTCs during treatment, with complete clearance after surgery. The dynamic change in CTC levels correlated with therapeutic response and potential recurrence risk. Conclusions: This pilot study highlights the clinical relevance of CTC monitoring in rectal cancer. CTC dynamics appear to reflect treatment efficacy and may serve as an early indicator of response. These findings support the development of a randomized clinical trial comparing rectal cancer treatments with and without neoadjuvant therapy, using CTC trends as a primary outcome measure.

Název v anglickém jazyce

Monitoring treatment response in rectal cancer through circulating tumor cell dynamics: a pilot clinical study

Popis výsledku anglicky

Background: Circulating tumor cells (CTCs) are increasingly recognized as a minimally invasive biomarker with significant potential in oncologic monitoring and prognostication. This study aimed to assess the dynamics of CTC levels in patients with rectal cancer undergoing multimodal treatment and evaluate their potential role in therapeutic decision-making. Methods: We conducted a prospective, observational study of 56 patients with histologically confirmed rectal adenocarcinoma. Patients underwent either primary surgical resection or neoadjuvant chemoradiotherapy (CRT) followed by surgery. Peripheral blood samples were collected at defined intervals and analyzed using the CytoTrack CT11TM system to detect and quantify CTCs. Results: Pretreatment CTCs were detected in 16.1% of patients. In the primary surgery group, all preoperatively positive CTC cases became negative postoperatively, although transient positivity was observed in two cases at 1 week post-surgery. In the CRT group, 35.7% of patients exhibited detectable CTCs during treatment, with complete clearance after surgery. The dynamic change in CTC levels correlated with therapeutic response and potential recurrence risk. Conclusions: This pilot study highlights the clinical relevance of CTC monitoring in rectal cancer. CTC dynamics appear to reflect treatment efficacy and may serve as an early indicator of response. These findings support the development of a randomized clinical trial comparing rectal cancer treatments with and without neoadjuvant therapy, using CTC trends as a primary outcome measure.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of surgical oncology

ISSN

0022-4790

e-ISSN

1096-9098

Svazek periodika

132

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

1052-1057

Kód UT WoS článku

001561398900001

EID výsledku v databázi Scopus

2-s2.0-105014871971